24/7 EEG SubQ for epilepsy (MIB277)Product type:AdviceProgramme:Medtech innovation briefingPublished: 2 November 2021
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 March 2023
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabis-based medicinal products (NG144)Product type:GuidanceProgramme:NICE guidelineLast updated: 22 March 2021Published: 11 November 2019
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cenobamate for treating focal onset seizures in epilepsy (TA753)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2021
Deep brain stimulation for refractory epilepsy in adults (IPG678)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 12 August 2020
Epilepsies in children, young people and adults (NG217)Product type:GuidanceProgramme:NICE guidelinePublished: 27 April 2022
Epilepsies in children, young people and adults (QS211)Product type:Quality standardPublished: 20 December 2023
Epilepsies in children, young people and adults (extraordinary review)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Fenfluramine for treating seizures associated with Dravet syndrome (TA808)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 July 2022
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 26 November 2024Expected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (IPG671)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 4 March 2020
MT650 24/7 EEG SubQ for people with epilepsyStatus:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Suspected neurological conditions: recognition and referral (NG127)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 1 May 2019
Suspected neurological conditions: recognition and referral (QS198)Product type:Quality standardPublished: 8 January 2021
Transcranial direct current stimulation (tDCS) for the treatment of refractory epilepsyStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Vagus nerve stimulation for refractory epilepsy in children (IPG50)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 March 2004